News for Gain Therapeutics, Inc. (GANX)

We recently published a list of Top 9 Healthcare Stocks to Buy According to Billionaire David Einhorn. In this article, we are going to take a look at where Gain Therapeutics, Inc.

Wall Street has come down crashing on President Donald Trump’s sweeping tariffs, raising the risk of a trade war that could push the global economy into recession.

Gain Therapeutics (GANX) recently showcased significant advancements in their research on GT-02287, a promising therapeutic candidate for Parkinson's disease, a

Preclinical data for GT-02287 shows promising disease-modifying potential in Parkinson's models. Phase 1b enrollment expected to complete by Q2 2025, wi

GT-02287 oral presentation demonstrates new evidence of disease-modifying capacity in GBA1 and idiopathic Parkinson's disease models Enrollment update provide

BETHESDA, Md., March 28, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. ( GANX) (”œGain”, or the ”œCompany”), a clinical-stage biotechnology company l

**media[579435]**

**media[578195]**

Interim Analysis Expected End of 2Q 2025BETHESDA, MD, Mar 14, 2025 - (ACN Newswire) - Gain Therapeutics, Inc. ( GANX), a clinical-stage biotechnology company le

**media[559111]**

**media[532899]**

Gain Therapeutics (GANX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

**media[507936]**

Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024 Gianluca Fuggetta Will Assume The Role Of Senior Vice President, Finance

Gain Therapeutics' GT-02287 shows promise in treating Parkinson's disease, with positive results and potential for market impact. Click here to read more.

Roth MKM keeps a Buy rating and $7 price target on Gain Therapeutics (GANX) after the company received approval from Australian regulators to begin GT-02287 evaluation in Parkinson’s disease patients. The firm believes that the Phase 1b study will deliver positive findings regarding safety, preliminary biochemical efficacy, and tolerability, the analyst tells investors in a research note. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try No

The Company has received approval to begin enrollment of the Phase 1b clinical trial in Australia Phase 1b clinical trial will assess safety and tolerability a

**media[499475]**

Presentation to Feature Lead Drug Candidate GT-02287 and Magellan Drug Discovery Platform BETHESDA, Md., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics